<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We report two patients with primary cutaneous B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> who were treated with rituximab, a new anti-CD20 monoclonal antibody </plain></SENT>
<SENT sid="1" pm="."><plain>The first patient, who had a diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> of the lower leg, achieved an 85% improvement </plain></SENT>
<SENT sid="2" pm="."><plain>The second patient, who had a primary cutaneous B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, which had undergone high-grade transformation and systemic spread, achieved a minor response of approximately 30% </plain></SENT>
<SENT sid="3" pm="."><plain>Both patients subsequently relapsed </plain></SENT>
<SENT sid="4" pm="."><plain>The first patient achieved complete clearance with a second course of rituximab given with systemic chemotherapy, but again relapsed </plain></SENT>
<SENT sid="5" pm="."><plain>Treatment with rituximab has been reported to produce response rates of 48% in relapsed systemic low-grade or follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, but there are no previous reports of the use of rituximab in primary cutaneous B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
</text></document>